Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Recursion Pharmaceuticals Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.84 (market cap $135.69M), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 15.8× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 61 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| GPTY | RXRX | |
|---|---|---|
Market Cap | $135.69M | $2.14B |
Volume | 97,442 | 30,789,535 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $6.79 |
52-Week Low | $34.73 | $2.84 |
Typical Hold Time | 61 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $42.84, down 0.76% with a bullish technical outlook from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.29-0.30, providing income generation. Recent coverage highlights the fund's AI-focused covered call strategy as offering high yield potential while retaining some upside participation in tech rallies.
The outlook remains positive for income-seeking investors, with the options-based strategy generating substantial distributions. Key risks include market volatility impacting the underlying AI portfolio and the trade-off between income generation and capital appreciation potential in strong bull markets.
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
